Dabrafenib (GSK2118436)

Catalog No.S2807

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Size Price Stock Quantity  
In DMSO USD 180 In stock
USD 90 In stock
USD 130 In stock
USD 170 In stock
USD 270 In stock
USD 400 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • BRAFi/MEKi-resistant A375DR and the parental A375 cells were treated with 2 μM vorinostat and/or the combination of 0.125 μM dabrafenib and 5 nM trametinib. Protein lysates were harvested after 72 hr. Western blot analysis was carried out for p-MEK and p-P90RSK as indicators of activation of MAPK pathway, ac-H3 as indicator for levels of acetylated histone H3 and a-tubulin as a loading control.

    Cell, 2018, 173(6):1413-1425. Dabrafenib (GSK2118436) purchased from Selleck.

    A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

    J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.

  • Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

    J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

    Immunoblotting of whole-cell lysates of WM1366 exposed to the indicated drugs for 48 hours using specific antibodies for phospho-acetyl CoA carboxylase (p-ACC), total acetyl CoA carboxylase (t-ACC), phospho-ERK1/2 (p-ERK1/2), and total ERK1/2 (t-ERK1/2). Immunoblots were quantified using ImageJ. The ratio of phosphorylated to total protein normalized to control is shown above the respective blots.

    Clin Cancer Res, 2018, 24(5):1090-1102. Dabrafenib (GSK2118436) purchased from Selleck.

  • Western blots for untreated, early, and late tumors.

    Cancer research, 2018, 78(2):542-557. Dabrafenib (GSK2118436) purchased from Selleck.

    Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

    Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

  • The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

    Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.

    Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

    PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.
Targets
B-Raf (V600E) [3]
(Cell-free assay)
B-Raf [3]
(Cell-free assay)
C-Raf [3]
(Cell-free assay)
0.7 nM 5.2 nM 6.3 nM
In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-RafV600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-RafV600E. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NXvT[3M6U2mwYYPlJGF{e2G7 MX\Jcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzJJRi\2enZDDCMXJi\iCYNkCwSUBufXSjboSg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIHnud4VkfCClZXzsd{Bkdy2neIDy[ZN{cW6pIFPER|M4KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJIJqd3SrbonsZZRm\C2PRVugdJJwfGWrbjDwbI9{eGixconsZZRqd25iYomgRYxxcGGVY4Ll[Y4h[XO|YYmge4l1cCCLQ{WwJI9nKDBwMECwO{DPxE1? NXy2cYo5OjR7MEC2O|M>
SK-MEL-28 M{\oUWtqdmG|ZTDBd5NigQ>? MkLwNUBp M3LHVGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIGPLMW1GVC1{ODDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBGWkticHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxPCEQvF2= NIXVTW0zPDlyME[3Ny=>
HepG2 MXTLbY5ie2ViQYPzZZk> MVjJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCHUlugdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByNDFOwG0> M2XWTVI1QTByNkez
COLO205 M3X3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfYTIxKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:yNFUh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjCwMlAxPyEQvF2= NYf6WmxsOjR7MEC2O|M>
HepG2 NW\NN2NOTnWwY4Tpc44hSXO|YYm= MmPiOFUhdWmw NHSxNXlFVVOR MV;Jcohq[mm2aX;uJI9nKEGua{WgbY4hXEeILXLleIEue3SrbYXsZZRm\CCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBUdWGmMjDwbI9{eGixconsZZRqd25idILlZZRm\CCob4KgOFUhdWmwczDwdolweiC2bzDUS2Yu[mW2YTDzeIlufWyjdHnvckBu\WG|dYLl[EBi\nSncjC2NEBucW6|IHL5JI9lgXO|ZYmgZoxwfCC|Y3HucoVzKGGwYXz5d4l{KHerdHigTWM2OCCxZjCzMlch|ryP MXOyOFkxODZ5Mx?=
HFF Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfPdXMyOCEQvF2= NFTwepY4OiCq MXrEUXNQ M4HlfGlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCqdX3hckBJTkZiY3XscJMhcGG{Yn;ybY5oKHerbHSgeJlx\SCELWLh[kB4cXSqIFnDOVAhd2ZiMzFOwG0> NWTiUpBMOjN6NESwN|g>
SK-MEL-28 NYjHWotyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\PT5MyOCEQvF2= MlPJO|IhcA>? MlS0SG1UVw>? NVfLfpQ6UW6qaXLpeIlwdiCxZjDCMXJi\iCYNkCwSUBufXSjboSt[JJqfmWwIGPLMW1GVC1{ODDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMESzJO69VQ>? NVTPdHlWOjN6NESwN|g>
A375P-F11 NHHIPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rzR|ExKM7:TR?= MnrkO|IhcA>? NEj6SWpFVVOR MoTqTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKEF|N{XQMWYyOSClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODdzIN88US=> MljxNlM5PDRyM{i=
MALME-3M NF3OUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOxNEDPxE1? MmXaO|IhcA>? MYrEUXNQ NVXlc|VmUUN3ME2xJI5O M4XmXlI{QDR2MEO4
UACC-62 M{nlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWixNEDPxE1? MV:3NkBp NFHnboZFVVOR MXTJR|UxRTFibl2= MXqyN|g1PDB|OB?=
C32TG NUmzVZFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTNNVAh|ryP M13Mc|czKGh? MX3EUXNQ MUfJR|UxRTFibl2= NHH0RVAzOzh2NECzPC=>
SK-MEL-1 MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVqxNEDPxE1? NULjWmJEPzJiaB?= NH71XFJFVVOR MVrJR|UxRTJibl2= M2\ne|I{QDR2MEO4
M14 NHPoS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XQcVExKM7:TR?= Mlq2O|IhcA>? NYPzTWlTTE2VTx?= NWrTNVB7UUN3ME2yJI5O MX:yN|g1PDB|OB?=
SK-MEL-28 M3rjXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XMO|ExKM7:TR?= Mnf3O|IhcA>? MX;EUXNQ M2TLOGlEPTB;MzDuUS=> M4TVNFI{QDR2MEO4
A375 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HpNVExKM7:TR?= Mmm1O|IhcA>? NFjW[Y9FVVOR NVXtUJdXUUN3ME20JI5O MVKyN|g1PDB|OB?=
DU-4475 NGrCSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XxdlExKM7:TR?= M1z4bVczKGh? MmLCSG1UVw>? NVLPe|FyUUN3ME21JI5O MmH5NlM5PDRyM{i=
UACC-257 NV\yfXdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TJNlExKM7:TR?= NETqZpo4OiCq NWHEXIZYTE2VTx?= M1vseWlEPTB;NjDuUS=> NHXEZmwzOzh2NECzPC=>
Colo 205 NXywPZk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17uUlExKM7:TR?= NGr2XJU4OiCq NWmwUGVvTE2VTx?= M3PzNWlEPTB;NzDuUS=> MW[yN|g1PDB|OB?=
SK-MEL-3 NVTOWopIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHMc3BxOTBizszN NVjOZmo2PzJiaB?= MXzEUXNQ NGPZOGZKSzVyPUegcm0> Moe0NlM5PDRyM{i=
SH-4 NFXXU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\5cos5OTBizszN MoHDO|IhcA>? NUe0eZg6TE2VTx?= NIDLW2tKSzVyPUigcm0> M2Xh[lI{QDR2MEO4
A101D NX3WN3FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[xNEDPxE1? MWS3NkBp MonzSG1UVw>? MX;JR|UxRTlibl2= NEHNO3AzOzh2NECzPC=>
ES-2 NX[5[JhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[zN|ExKM7:TR?= NY\YW3RsPzJiaB?= M2jJVGROW09? Mki2TWM2OD13MzDuUS=> MXyyN|g1PDB|OB?=
HT-29 M{HSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuxNEDPxE1? M2nrS|czKGh? MXrEUXNQ MXLJR|UxRTZ4IH7N NWLmeXJ2OjN6NESwN|g>
SW1417 MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHneJIyOCEQvF2= NWTnb5ZKPzJiaB?= NUDHO5lYTE2VTx?= NXf1Vmw3UUN3ME2xOVghdk1? NUPkdYtsOjN6NESwN|g>
SW872 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW1NVAh|ryP M4[4UlczKGh? NX7QdFRDTE2VTx?= MnnNTWM2OD1|N{egcm0> Mkj5NlM5PDRyM{i=
RKO M2\Dc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLJNVAh|ryP MX23NkBp NHXGXFdFVVOR M2\M[mlEPTB;Mj61NlIh|ryP MnXSNlM5PDRyM{i=
A673 MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXixNEDPxE1? NW[yN2lIPzJiaB?= NVHGUVlFTE2VTx?= M4rDRmlEPTB;MUCg{txO MnT4NlM5PDRyM{i=
GCT NEPvWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{joVFExKM7:TR?= MUS3NkBp M1fWZ2ROW09? M2DKXGlEPTB;MUCg{txO NUTCXHhROjN6NESwN|g>
WM-115 NVTZdIxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\JZpcyOCEQvF2= M3HjTFczKGh? NYjTW2V{TE2VTx?= NVzzU4FsUUN3ME21JI5O NEPCO5IzOzh2NECzPC=>
YUMAC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DWSlExKM7:TR?= M{\3RVczKGh? MYTEUXNQ MW\JR|UxRTVibl2= Mm\SNlM5PDRyM{i=
OV-90 Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[x[pkyOCEQvF2= NX\vOG1CPzJiaB?= MYTEUXNQ NWXxS|hSUUN3ME2yPUBvVQ>? NXX2WY1COjN6NESwN|g>
NCI-H508 Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXexNEDPxE1? NWTnR2JKPzJiaB?= MknCSG1UVw>? NFrlUHJKSzVyPUGwJO69VQ>? NYfrcWQ{OjN6NESwN|g>
MDA-MB-231 NXjtW49kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmmwNVAh|ryP M{W0VlczKGh? NGj6UmNFVVOR MnzpTWM2OD1zMDFOwG0> M{fVR|I{QDR2MEO4
SW756 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPjNVAh|ryP NFHRdWs4OiCq NVPwVXF2TE2VTx?= M1PsfmlEPTB;MUCg{txO NFTLUGMzOzh2NECzPC=>
SW-837 NIn3Z3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[xNEDPxE1? NYi1bXN2PzJiaB?= M1HSc2ROW09? MkLjTWM2OD1zMDFOwG0> M4fxUVI{QDR2MEO4
UMUC-3 NH;FU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r6fVExKM7:TR?= M1q2XlczKGh? NVKxbWlDTE2VTx?= NILJOlNKSzVyPUGwJO69VQ>? NUP6bYVyOjN6NESwN|g>
LS-174T NILuWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[xNEDPxE1? MXG3NkBp M4nuPGROW09? MVnJR|UxRTFyIN88US=> Ml;wNlM5PDRyM{i=
A549 M2XtT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon0NVAh|ryP M{fJflczKGh? M1fBeGROW09? NXfWZox5UUN3ME2xNEDPxE1? NF3TNGkzOzh2NECzPC=>
SHP-77 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTtWppKOTBizszN NEXueXk4OiCq MU\EUXNQ M3\ldmlEPTB;MUCg{txO NH35b5QzOzh2NECzPC=>
SW480 M4jifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWxNEDPxE1? MYO3NkBp M2nYbWROW09? NFXpR3ZKSzVyPUGwJO69VQ>? M4fGRlI{QDR2MEO4
DLD-1 MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\4V4ZpOTBizszN M4rDTFczKGh? M{fWbWROW09? NGj5[4hKSzVyPUGwJO69VQ>? NX7xW3N3OjN6NESwN|g>
HCT-116 Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT1dJQyOCEQvF2= NGWySHE4OiCq M3TCR2ROW09? NEf1R|dKSzVyPUGwJO69VQ>? MX:yN|g1PDB|OB?=
NCI-H747 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3m4PVExKM7:TR?= Mn7nO|IhcA>? NUDIflhDTE2VTx?= MlzITWM2OD1zMDFOwG0> Mon6NlM5PDRyM{i=
T-84 NHnWXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmmzNVAh|ryP MYG3NkBp M1LDS2ROW09? NIH0eHhKSzVyPUGwJO69VQ>? NVvsRppkOjN6NESwN|g>
NCI-H460 M4fXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnablcyOCEQvF2= MofMO|IhcA>? MWDEUXNQ M361cWlEPTB;MUCg{txO MXuyN|g1PDB|OB?=
Calu-6 MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojvNVAh|ryP M3zGV|czKGh? M4T2SmROW09? NFLYfXNKSzVyPUGwJO69VQ>? M2\KUVI{QDR2MEO4
HCC-2998 MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[4NVAh|ryP M3TSc|czKGh? MmHwSG1UVw>? NVzlTFdJUUN3ME2xNEDPxE1? NUmxdJA3OjN6NESwN|g>
LS1034 Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi2coU4OTBizszN NILD[HQ4OiCq NYPCdlB{TE2VTx?= NGe2PZhKSzVyPUGwJO69VQ>? MkTtNlM5PDRyM{i=
CHP-212 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWexNEDPxE1? NWC5TohmPzJiaB?= MlTuSG1UVw>? NFzVfoZKSzVyPUGwJO69VQ>? NFrQUnIzOzh2NECzPC=>
SK-N-AS NYjDbXE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm1O5UyOCEQvF2= MlPCO|IhcA>? M{TLOmROW09? M4TUTWlEPTB;MUCg{txO NVrPNWRHOjN6NESwN|g>
BFTC-905 NW[0UFkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3CNVAh|ryP MXS3NkBp NFjhSYNFVVOR MlzMTWM2OD1zMDFOwG0> NGL0eYczOzh2NECzPC=>
HuT78 M3vYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK3PW9kOTBizszN NXzCO5o3PzJiaB?= Mn7ZSG1UVw>? NUn6W5c4UUN3ME21NkBvVQ>? NFvOO3czOzh2NECzPC=>
RPMI-8226 MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWxNEDPxE1? NXjYS|A3PzJiaB?= MWHEUXNQ M2jpSGlEPTB;Mk[zJI5O NGr3WHczOzh2NECzPC=>
BC-3 Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z3RVExKM7:TR?= NF\3XVk4OiCq MlvXSG1UVw>? MlPNTWM2OD1{N{egcm0> M4CwTlI{QDR2MEO4
ACHN MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rtU|ExKM7:TR?= Ml\WO|IhcA>? NF;1SlBFVVOR NGDkNHdKSzVyPUK5OEBvVQ>? M3rXdFI{QDR2MEO4
JRT3-T35 M{XCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;F[JcyOCEQvF2= MnfWO|IhcA>? NIrmeoZFVVOR Mne2TWM2OD1{OUWgcm0> MX6yN|g1PDB|OB?=
SK-MES-1 NWfvTpVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HYOFExKM7:TR?= MUW3NkBp NU\TUZRsTE2VTx?= M1XPXmlEPTB;M{K5JI5O NUjKe401OjN6NESwN|g>
CESS MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELoXpIyOCEQvF2= NHH4clY4OiCq MknMSG1UVw>? NF[3bYlKSzVyPUS5O{BvVQ>? NYfC[|BIOjN6NESwN|g>
H4 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV2xNEDPxE1? NWnieWlFPzJiaB?= NIPEcVFFVVOR MlzqTWM2OD14MUmgcm0> M4jhXFI{QDR2MEO4
BC-1 NIW4TVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDTU3YyOCEQvF2= NUXVZXo2PzJiaB?= MmKwSG1UVw>? M4fGNmlEPTB;N{C0JI5O MnfNNlM5PDRyM{i=
DB MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknwNVAh|ryP MUi3NkBp NVHYOXlkTE2VTx?= M1exWGlEPTB;OEezJI5O NEjqeYMzOzh2NECzPC=>
RPMI-6666 Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF71NnYyOCEQvF2= MWK3NkBp M2HyTGROW09? M{T4SmlEPTB;OUK4JI5O MViyN|g1PDB|OB?=
MC/CAR NHv5cmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17nXVExKM7:TR?= NV;Gdm84PzJiaB?= Ml;OSG1UVw>? M3TZcGlEPTB;MT6wNFIh|ryP NGe0WY0zOzh2NECzPC=>
SNU-1 Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGxNEDPxE1? M4C0VVczKGh? MWDEUXNQ MkPOTWM2OD1zLkWwNUDPxE1? MWSyN|g1PDB|OB?=
CEM/C1 M{PRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;N[lJuOTBizszN MWm3NkBp M2PoNmROW09? NYOxS5lwUUN3ME2xMlc4OyEQvF2= M4D3OlI{QDR2MEO4
GDM-1 M4jISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jvT|ExKM7:TR?= NH;COm84OiCq MVvEUXNQ M1PoemlEPTB;MT65PVch|ryP M1jRVFI{QDR2MEO4
HT-1080 NGfrcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTDNVAh|ryP M{jyNFczKGh? NILJfYRFVVOR M4qyTWlEPTB;Mj6wNFQh|ryP MojpNlM5PDRyM{i=
HL-60 NUDKOFM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGxNEDPxE1? M1HlZ|czKGh? Mn:4SG1UVw>? NXLjRoNiUUN3ME2yMlE4QCEQvF2= NF;2fpozOzh2NECzPC=>
C3A MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUKxNEDPxE1? MkP0O|IhcA>? MY\EUXNQ M3HXOWlEPTB;NT60NVQh|ryP NW\oPXJwOjN6NESwN|g>
MES-SA NV\Fd4RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnseWgyOCEQvF2= MkXxO|IhcA>? MmLQSG1UVw>? MYfJR|UxRTZwOUi5JO69VQ>? MmLZNlM5PDRyM{i=
22Rv1 NHLwN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoH0NVAh|ryP M1nEe|czKGh? MoXBSG1UVw>? MliwTWM2OD1zMDFOwG0> NIf0dFgzOzh2NECzPC=>
647-V M3XWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq4OWhoOTBizszN Mmi1O|IhcA>? MWTEUXNQ M3rDZWlEPTB;MUCg{txO M1r6ZlI{QDR2MEO4
786-O MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXZNVAh|ryP M2LEcFczKGh? NGfDd2pFVVOR NFLSXItKSzVyPUGwJO69VQ>? MV:yN|g1PDB|OB?=
A172 NXLpfYtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv4PVQyOCEQvF2= M1XsbFczKGh? NGqz[YhFVVOR MUDJR|UxRTFyIN88US=> NFjSOGMzOzh2NECzPC=>
A204 M2nyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfIeJcyOCEQvF2= Mkm1O|IhcA>? MXTEUXNQ MkDoTWM2OD1zMDFOwG0> M1vN[lI{QDR2MEO4
A427 NEj2XmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYWxNEDPxE1? NWT5W2xWPzJiaB?= M1PGeWROW09? NWLVOopbUUN3ME2xNEDPxE1? NV3CUW1YOjN6NESwN|g>
A431 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TXbVExKM7:TR?= MV63NkBp MUDEUXNQ MVzJR|UxRTFyIN88US=> M{XwVlI{QDR2MEO4
A2780 MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqxNEDPxE1? MVe3NkBp MXrEUXNQ M4Lib2lEPTB;MUCg{txO NHfkXWEzOzh2NECzPC=>
ARH-77 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDHXZU4OTBizszN M2KyfFczKGh? MnrpSG1UVw>? M1vUb2lEPTB;MUCg{txO M1jHPFI{QDR2MEO4
Be(2)C MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzRbZJROTBizszN M4GzOFczKGh? Mnj4SG1UVw>? MnrETWM2OD1zMDFOwG0> M2Pnc|I{QDR2MEO4
BT-20 NGLnN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vXPFExKM7:TR?= NHvvWlU4OiCq M{HyVWROW09? M2K3UWlEPTB;MUCg{txO NETHOVEzOzh2NECzPC=>
BxPc3 MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPYVlQyOCEQvF2= NI\NfXk4OiCq M4npNWROW09? M4TXb2lEPTB;MUCg{txO M3\JOFI{QDR2MEO4
C-4 I MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HIc|ExKM7:TR?= M4nGelczKGh? NHX5T4dFVVOR NWnRbGNKUUN3ME2xNEDPxE1? M3jJ[lI{QDR2MEO4
C33A NYT4PFliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH61SJIyOCEQvF2= NGj4Uog4OiCq MkK0SG1UVw>? NYm4cWNsUUN3ME2xNEDPxE1? NUeyVHdVOjN6NESwN|g>
CAL-27 NHnVRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYixNEDPxE1? MYW3NkBp NVPKZXNOTE2VTx?= NH[4WIJKSzVyPUGwJO69VQ>? MYWyN|g1PDB|OB?=
CAL-62 M3raS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGflTowyOCEQvF2= MWq3NkBp MVrEUXNQ NF3ydppKSzVyPUGwJO69VQ>? MlLyNlM5PDRyM{i=
Calu-3 Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rwclExKM7:TR?= MYe3NkBp MmXFSG1UVw>? MnnMTWM2OD1zMDFOwG0> NU\TTFZjOjN6NESwN|g>
CaOV3 NVjl[lRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnmNVAh|ryP M{jwOFczKGh? NVTPeVRzTE2VTx?= NWn1W4t2UUN3ME2xNEDPxE1? NEHmcI0zOzh2NECzPC=>
CGTHW1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LWeFExKM7:TR?= NUjzUIZZPzJiaB?= M1jLTGROW09? Mn7OTWM2OD1zMDFOwG0> M1znSlI{QDR2MEO4
CHL-1 NGn5TYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\wZYloOTBizszN NFmz[XQ4OiCq MXPEUXNQ NYjl[FlGUUN3ME2xNEDPxE1? NWKxSWNPOjN6NESwN|g>
Colo320DM M{e5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjmelNNOTBizszN NIPpcmU4OiCq NV36Tpd[TE2VTx?= MkjSTWM2OD1zMDFOwG0> Ml\5NlM5PDRyM{i=
Colo704 NF6wb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLtNVAh|ryP MUS3NkBp M{LWW2ROW09? MonkTWM2OD1zMDFOwG0> NFXIV3gzOzh2NECzPC=>
COR-L23 NGi1bXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFqwXWcyOCEQvF2= M4HaVlczKGh? M4DkeGROW09? MVzJR|UxRTFyIN88US=> MUmyN|g1PDB|OB?=
CRO-AP2 Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyxNEDPxE1? NXzBSXg5PzJiaB?= MW\EUXNQ NXvFUFhPUUN3ME2xNEDPxE1? M{fscFI{QDR2MEO4
Daudi MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjWVYVFOTBizszN NGLCNFY4OiCq MY\EUXNQ MnLQTWM2OD1zMDFOwG0> M3mzcVI{QDR2MEO4
DOTC 24510 NWr0c5FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDkNVAh|ryP NGSyOYY4OiCq NYOxb2JJTE2VTx?= MnHPTWM2OD1zMDFOwG0> NGL6R20zOzh2NECzPC=>
DU-145 NVX4dG9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfYNlFrOTBizszN NUP6S|hrPzJiaB?= NIWwSYVFVVOR NFTN[nJKSzVyPUGwJO69VQ>? M{\Y[FI{QDR2MEO4
EB-3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknwNVAh|ryP NWOwdWxtPzJiaB?= MWTEUXNQ NHH5fJVKSzVyPUGwJO69VQ>? Mkf6NlM5PDRyM{i=
EFM-19 Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S1fVExKM7:TR?= NI[zeGo4OiCq NVi3OVhLTE2VTx?= NXPqdY5SUUN3ME2xNEDPxE1? MViyN|g1PDB|OB?=
EKVX MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLGNVAh|ryP NHLUZng4OiCq MV3EUXNQ MX7JR|UxRTFyIN88US=> NVXwfnlMOjN6NESwN|g>
FaDu MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrGNVAh|ryP NITuVJI4OiCq NIixNYFFVVOR NEfpR4dKSzVyPUGwJO69VQ>? MmnGNlM5PDRyM{i=
G401 MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPzXog3OTBizszN NWDSOIxmPzJiaB?= M1S2UWROW09? MofXTWM2OD1zMDFOwG0> M3\uSFI{QDR2MEO4
HCC-70 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH0NVAh|ryP M3nNcFczKGh? M1HKRWROW09? M2LRU2lEPTB;MUCg{txO NInnblczOzh2NECzPC=>
HCC-1954 NGTNfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\vNVAh|ryP M1voUFczKGh? NUjvd41bTE2VTx?= NH\tXpdKSzVyPUGwJO69VQ>? MmnPNlM5PDRyM{i=
Hela NFPVOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKxNEDPxE1? M2\ZfVczKGh? MmPwSG1UVw>? M4\FT2lEPTB;MUCg{txO NWCxOYtmOjN6NESwN|g>
Hep3B NHvTO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnWb2IyOCEQvF2= NFnufJM4OiCq MWnEUXNQ MYTJR|UxRTFyIN88US=> NEfv[2UzOzh2NECzPC=>
HMCB M1jK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKxNEDPxE1? MWm3NkBp M2W4d2ROW09? MU\JR|UxRTFyIN88US=> Mki3NlM5PDRyM{i=
HN5 NICzfldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjONVAh|ryP MoHBO|IhcA>? NWfRXoZkTE2VTx?= M{XOb2lEPTB;MUCg{txO M1HxUFI{QDR2MEO4
HOS Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3JUoMyOCEQvF2= MUK3NkBp M1nBU2ROW09? NGPwfIlKSzVyPUGwJO69VQ>? Mo\YNlM5PDRyM{i=
HPAF-II NFXBbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOxNEDPxE1? M3;6fFczKGh? M1fxbWROW09? NGjwT5hKSzVyPUGwJO69VQ>? NX\mVVBZOjN6NESwN|g>
Hs746.T NXjsNIl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjaSGxjOTBizszN Moj2O|IhcA>? NUfwVVRPTE2VTx?= MVnJR|UxRTFyIN88US=> NX\PSmxrOjN6NESwN|g>
HT M3fYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPl[nMyOCEQvF2= NI\jNIQ4OiCq MnHMSG1UVw>? Mkn2TWM2OD1zMDFOwG0> M2HZNFI{QDR2MEO4
HT-3 NWHx[XRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV2xNEDPxE1? NEjFc3M4OiCq MVnEUXNQ NWHVZ45GUUN3ME2xNEDPxE1? M2jYblI{QDR2MEO4
HuNS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfwd4wyOCEQvF2= NXuydIhTPzJiaB?= NEHybJFFVVOR MoTQTWM2OD1zMDFOwG0> MWCyN|g1PDB|OB?=
IGROV1 NVj2XVMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUixNEDPxE1? NFTzfY44OiCq M17sVGROW09? M4q5OmlEPTB;MUCg{txO NGi5OHUzOzh2NECzPC=>
J82 MnO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrofXIyOCEQvF2= MmjRO|IhcA>? M4\jemROW09? MUHJR|UxRTFyIN88US=> NVnuUHNnOjN6NESwN|g>
JM1 M{\TUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLUUYdmOTBizszN M1jKWVczKGh? MkPoSG1UVw>? MlXrTWM2OD1zMDFOwG0> NYjIT2dMOjN6NESwN|g>
Kato III NVr1OItFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUexNEDPxE1? NETZZnI4OiCq M3XRUmROW09? MnvpTWM2OD1zMDFOwG0> NULzZWlJOjN6NESwN|g>
KHOS-240S M1nRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX1UmUyOCEQvF2= MmfJO|IhcA>? Mk[zSG1UVw>? NFzSbVhKSzVyPUGwJO69VQ>? M3rVbVI{QDR2MEO4
KM-12 Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrFNVAh|ryP M{PMb|czKGh? Mn3vSG1UVw>? NUDpT|NCUUN3ME2xNEDPxE1? MYeyN|g1PDB|OB?=
KPL-1 M3rmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\zflExKM7:TR?= MorKO|IhcA>? MYPEUXNQ NHnLb2RKSzVyPUGwJO69VQ>? MU[yN|g1PDB|OB?=
KYSE-30 NXvtbGhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVqxN25COTBizszN MXu3NkBp M3TTR2ROW09? M{Cy[2lEPTB;MUCg{txO MYGyN|g1PDB|OB?=
LNCaP NIjD[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q1XVExKM7:TR?= NHGyVmk4OiCq MnfMSG1UVw>? NH3BR4RKSzVyPUGwJO69VQ>? M2TWblI{QDR2MEO4
MCF-7 MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHDdIpYOTBizszN MX23NkBp MXXEUXNQ NVTtZm91UUN3ME2xNEDPxE1? NH\mXXYzOzh2NECzPC=>
MC-IXC NVvvRYVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HyZVExKM7:TR?= NXvMTIJMPzJiaB?= NEezN3RFVVOR M2L4e2lEPTB;MUCg{txO M1i4clI{QDR2MEO4
MDA-MB-175 VII NFL1WXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\N[5hzOTBizszN Mk[xO|IhcA>? NHP3b41FVVOR M{jwcWlEPTB;MUCg{txO MWWyN|g1PDB|OB?=
MDA-MB-468 NVu5R4dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmxNVAh|ryP M2i2XFczKGh? MWTEUXNQ MnHLTWM2OD1zMDFOwG0> NWn3SlN2OjN6NESwN|g>
MiaPaCa NEXvTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\6NVAh|ryP NXnZR|dFPzJiaB?= NYXtXIFETE2VTx?= NXXHZVhKUUN3ME2xNEDPxE1? M1n2SlI{QDR2MEO4
Molt-4 MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;s[2MyOCEQvF2= M3jxSVczKGh? Mk\tSG1UVw>? MmXyTWM2OD1zMDFOwG0> M4rIb|I{QDR2MEO4
NCI-ADR/RES MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H3TlExKM7:TR?= MlG1O|IhcA>? NUjHNYhTTE2VTx?= NUfDXFdIUUN3ME2xNEDPxE1? M1zV[FI{QDR2MEO4
NCI-H69 MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Swe|ExKM7:TR?= MWO3NkBp M1G5XGROW09? M1;HeWlEPTB;MUCg{txO NXH4UGl7OjN6NESwN|g>
NCI-H82 Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\vdnZKOTBizszN NIH5Z4g4OiCq NUKz[WhwTE2VTx?= NYXTUVJlUUN3ME2xNEDPxE1? NWLuV29YOjN6NESwN|g>
NCI-N87 NIC4fXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn3cWc{OTBizszN MYK3NkBp MnTjSG1UVw>? Mkj3TWM2OD1zMDFOwG0> NXXLXmY{OjN6NESwN|g>
NCI-H146 M3[zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DtbFExKM7:TR?= MWC3NkBp MnzISG1UVw>? MlTCTWM2OD1zMDFOwG0> MlW1NlM5PDRyM{i=
NCI-H157 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnMUVNHOTBizszN NW\DPW5jPzJiaB?= MWnEUXNQ MX\JR|UxRTFyIN88US=> NIW3RVMzOzh2NECzPC=>
NCI-H187 M{T5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXyxNEDPxE1? NIH6ZZk4OiCq NWnqSFAxTE2VTx?= MUDJR|UxRTFyIN88US=> NGLmOWIzOzh2NECzPC=>
NCI-H209 M13MZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTPeXZWOTBizszN M3PmTVczKGh? NVLxZpRbTE2VTx?= NGP6fJhKSzVyPUGwJO69VQ>? NWrPeW1VOjN6NESwN|g>
NCI-H226 NFO0fY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfnWIcyOCEQvF2= MV23NkBp MnKxSG1UVw>? NIfWTpVKSzVyPUGwJO69VQ>? NIGzc3ozOzh2NECzPC=>
NCI-H292 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\HNVAh|ryP NUW5SZh5PzJiaB?= MkXrSG1UVw>? MmnXTWM2OD1zMDFOwG0> NUH2Z4xuOjN6NESwN|g>
NCI-H322 M{fYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjlWHVtOTBizszN MXS3NkBp M4jvcmROW09? M1:5ZmlEPTB;MUCg{txO M1G5fVI{QDR2MEO4
NCI-H358 M1LYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojONVAh|ryP NUXPc4c6PzJiaB?= NInmeGFFVVOR NInHOFFKSzVyPUGwJO69VQ>? M1nWZlI{QDR2MEO4
NCI-H520 NHLRXHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vQb|ExKM7:TR?= M1TxWVczKGh? MU\EUXNQ NUH2e4xFUUN3ME2xNEDPxE1? M4rScVI{QDR2MEO4
NCI-H526 NXnveXBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHJSGdyOTBizszN NEi1dGs4OiCq NGXZWpBFVVOR NH3M[|VKSzVyPUGwJO69VQ>? NHziWZMzOzh2NECzPC=>
NCI-H630 MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3LO2ZDOTBizszN M3fWWlczKGh? NWPWepk5TE2VTx?= M{fHUGlEPTB;MUCg{txO NIDmbIczOzh2NECzPC=>
NCI-H661 NX\TTpZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf1NVAh|ryP MWi3NkBp MkiwSG1UVw>? NHXqNYNKSzVyPUGwJO69VQ>? MX6yN|g1PDB|OB?=
NCI-H716 NYnkbmtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDMW40yOCEQvF2= NGnQNYQ4OiCq MYnEUXNQ NYnvTII{UUN3ME2xNEDPxE1? NX3HO5Z6OjN6NESwN|g>
NCI-H1563 M3n6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz5[nhKOTBizszN MUe3NkBp NYC5fm4zTE2VTx?= MUjJR|UxRTFyIN88US=> NEi2fXMzOzh2NECzPC=>
NCI-H1792 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfCNVAh|ryP M3e3cVczKGh? MofaSG1UVw>? NEnuXlRKSzVyPUGwJO69VQ>? NYDhOZY3OjN6NESwN|g>
NCI-H2030 NVzRcG16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLHcVB3OTBizszN M{O3PFczKGh? MlGzSG1UVw>? NX\tTow4UUN3ME2xNEDPxE1? MlnnNlM5PDRyM{i=
NCI-H2052 M1TnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\TNVAh|ryP NVXuNIVLPzJiaB?= MXrEUXNQ NVz3ToZHUUN3ME2xNEDPxE1? MmLPNlM5PDRyM{i=
NCI-H2122 MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCxNEDPxE1? NHX5VIE4OiCq Mn7ESG1UVw>? MkD5TWM2OD1zMDFOwG0> MXKyN|g1PDB|OB?=
NCI-H2228 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T2O|ExKM7:TR?= NGTYTWM4OiCq MmjrSG1UVw>? MXLJR|UxRTFyIN88US=> NHXyeIEzOzh2NECzPC=>
OE-19 M{XCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTZNVAh|ryP MVW3NkBp NFXwdFlFVVOR NWfne2I1UUN3ME2xNEDPxE1? NX7Zc2RkOjN6NESwN|g>
OE-21 MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj6NVAh|ryP M4\MVFczKGh? MUnEUXNQ Mn\hTWM2OD1zMDFOwG0> NHnwSJYzOzh2NECzPC=>
OE-33 NU[yZZpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDXNVAh|ryP NHu2SmU4OiCq MULEUXNQ M4[5UGlEPTB;MUCg{txO MlzTNlM5PDRyM{i=
OVCAR-3 M2XZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW1NVAh|ryP MVK3NkBp MUXEUXNQ MUnJR|UxRTFyIN88US=> NU\jXldNOjN6NESwN|g>
OVCAR-4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3tVpAyOCEQvF2= NFradmE4OiCq NH23dYdFVVOR MVrJR|UxRTFyIN88US=> M2XiOlI{QDR2MEO4
OVCAR-5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[zZnM5OTBizszN MVe3NkBp MUXEUXNQ MkTNTWM2OD1zMDFOwG0> Ml[yNlM5PDRyM{i=
P3HR-1 M1LoSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvhNVAh|ryP MWO3NkBp MYrEUXNQ MVzJR|UxRTFyIN88US=> M37zVFI{QDR2MEO4
PC-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknENVAh|ryP NIGyUG04OiCq MYjEUXNQ M1Ppb2lEPTB;MUCg{txO NHTjWJozOzh2NECzPC=>
Raji MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\Ud2QyOTBizszN NXTWVZRIPzJiaB?= MX3EUXNQ M13ZOWlEPTB;MUCg{txO M2\jSFI{QDR2MEO4
RD MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITRT4kyOCEQvF2= NIrJ[Yo4OiCq Mn7kSG1UVw>? NFWybWVKSzVyPUGwJO69VQ>? NYrQXY5XOjN6NESwN|g>
RD-ES NVzuW2pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\HNVAh|ryP NIDEVmo4OiCq M2PNOmROW09? NITUS4lKSzVyPUGwJO69VQ>? Mn61NlM5PDRyM{i=
RL M{j1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3judlExKM7:TR?= NFXncpI4OiCq MWnEUXNQ MYfJR|UxRTFyIN88US=> NGHtbFMzOzh2NECzPC=>
SaOS2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvGcJBpOTBizszN NUfMSGJ{PzJiaB?= NV3xS4F1TE2VTx?= M{DaVGlEPTB;MUCg{txO NIrGUnMzOzh2NECzPC=>
SCC-9 MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTyenp6OTBizszN NFXObmU4OiCq MUnEUXNQ MnHhTWM2OD1zMDFOwG0> M1zlXFI{QDR2MEO4
SCC-12 M4\QU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXyxNEDPxE1? NYTKOGFlPzJiaB?= NYSy[IdVTE2VTx?= MX\JR|UxRTFyIN88US=> M1foRlI{QDR2MEO4
SCC-13 NITq[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfPNVAh|ryP NIjSbmU4OiCq M{XqWmROW09? NYXYO29IUUN3ME2xNEDPxE1? M2XucVI{QDR2MEO4
SCC-15 M1nZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXSxcFBoOTBizszN NH7SV2s4OiCq MXTEUXNQ NYLnZWk5UUN3ME2xNEDPxE1? NF3ieZIzOzh2NECzPC=>
SCC-25 NHvOd|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXntWIY3OTBizszN MlfMO|IhcA>? NGXjZWxFVVOR MXXJR|UxRTFyIN88US=> M2nPOVI{QDR2MEO4
SCLC-3 M1vIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\mTmYyOCEQvF2= M3;X[FczKGh? MkfqSG1UVw>? Ml3oTWM2OD1zMDFOwG0> MnnHNlM5PDRyM{i=
SF-268 NEjCc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX0UogyOCEQvF2= NH[ydZU4OiCq NFHkW|VFVVOR M2[zbWlEPTB;MUCg{txO MoTuNlM5PDRyM{i=
SF-295 NW[ydGwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWCxNEDPxE1? M{m1VlczKGh? MoHGSG1UVw>? M2\QNGlEPTB;MUCg{txO NWXuXHRFOjN6NESwN|g>
SJRH30 M1PYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzxRlgyOCEQvF2= NGrz[ng4OiCq M1\SOGROW09? NW[2enJXUUN3ME2xNEDPxE1? NY\vNopuOjN6NESwN|g>
SK-BR-3 M2jKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDPcpIyOCEQvF2= M1HWTFczKGh? M{GxRWROW09? M3rxSWlEPTB;MUCg{txO NYjSToIzOjN6NESwN|g>
SK-LMS-1 NVPndox5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fpRlExKM7:TR?= M3vrNlczKGh? NGfjN5lFVVOR NGPHcoRKSzVyPUGwJO69VQ>? MknONlM5PDRyM{i=
SK-N-DZ M3q2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnB[ItVOTBizszN NVfyWHdiPzJiaB?= NWH2dFZGTE2VTx?= NHvhUINKSzVyPUGwJO69VQ>? M{P3ZVI{QDR2MEO4
SK-N-F1 NUDZR3Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWSxNEDPxE1? M1PldVczKGh? NGTEVJZFVVOR M2TUN2lEPTB;MUCg{txO NEX6OpYzOzh2NECzPC=>
SKOV-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13OTVExKM7:TR?= MX23NkBp NH[0UItFVVOR NU\Z[WNUUUN3ME2xNEDPxE1? M131T|I{QDR2MEO4
SK-UT-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCxNEDPxE1? MnvBO|IhcA>? M4\KWmROW09? MnLtTWM2OD1zMDFOwG0> MmrWNlM5PDRyM{i=
SN12C M2Dtcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvvSnZVOTBizszN NEO0[Zk4OiCq MojYSG1UVw>? NW\IUYpsUUN3ME2xNEDPxE1? Mm\ZNlM5PDRyM{i=
SNB-19 NWDI[|h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHWRXFROTBizszN MXm3NkBp NH[2T|lFVVOR MlviTWM2OD1zMDFOwG0> MUSyN|g1PDB|OB?=
SNU-5 M1[wTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jnV|ExKM7:TR?= NWG5emtZPzJiaB?= NFi5OVhFVVOR M1TBXGlEPTB;MUCg{txO NF7kSFYzOzh2NECzPC=>
SNU-16 NHf4W2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonqNVAh|ryP MoXzO|IhcA>? M4ey[2ROW09? NXL3TIdCUUN3ME2xNEDPxE1? MVWyN|g1PDB|OB?=
SNU-398 NUDhd3d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf4fnBUOTBizszN Mk\QO|IhcA>? M2POWWROW09? MkXJTWM2OD1zMDFOwG0> NUnMTIpiOjN6NESwN|g>
SNU-449 NXzaTGxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PsT|ExKM7:TR?= M3zhdVczKGh? MYDEUXNQ M{nsdWlEPTB;MUCg{txO M2jsblI{QDR2MEO4
SR M{XuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHOwS24yOCEQvF2= M3[1N|czKGh? M2XPXWROW09? MWrJR|UxRTFyIN88US=> NFHJUY4zOzh2NECzPC=>
ST486 M{SxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnQZ5BOOTBizszN NUjaT3NqPzJiaB?= M1\kdGROW09? NULPTW1kUUN3ME2xNEDPxE1? M37FflI{QDR2MEO4
SW579 NHK5dm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17uNFExKM7:TR?= NFK5d3Y4OiCq MVfEUXNQ NWH0WFFVUUN3ME2xNEDPxE1? M{PIcFI{QDR2MEO4
SW684 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\5NVAh|ryP MUC3NkBp NHHzcXRFVVOR NYToeoZXUUN3ME2xNEDPxE1? NXXoc49[OjN6NESwN|g>
SW-780 NWTU[4tYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzPOVYyOCEQvF2= NHzOeI04OiCq NGnybllFVVOR NYnhNVFTUUN3ME2xNEDPxE1? MUKyN|g1PDB|OB?=
SW900 MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vFVVExKM7:TR?= NIXyOoo4OiCq NHjrXmRFVVOR M2DMXGlEPTB;MUCg{txO MmjQNlM5PDRyM{i=
SW1088 NF\abW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvFeGoyOCEQvF2= MkLXO|IhcA>? Mn23SG1UVw>? Ml7XTWM2OD1zMDFOwG0> NHnXXY8zOzh2NECzPC=>
SW1463 M2f3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XhNFExKM7:TR?= M4HncFczKGh? Mn6ySG1UVw>? NIPzTIRKSzVyPUGwJO69VQ>? NV;ldItjOjN6NESwN|g>
SW1990 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLZe3pvOTBizszN NWDIWm1lPzJiaB?= MlrYSG1UVw>? MojETWM2OD1zMDFOwG0> MX:yN|g1PDB|OB?=
T47D MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{S1eVExKM7:TR?= NFrrXW04OiCq M{PHWmROW09? M3PafGlEPTB;MUCg{txO NULDdVFyOjN6NESwN|g>
TE381.T M{nyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;5eZIyOCEQvF2= M2DX[|czKGh? Mnr1SG1UVw>? NFHsZ4hKSzVyPUGwJO69VQ>? MlT4NlM5PDRyM{i=
TK-10 NX;TUVhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXOVYh5OTBizszN NHjRSWg4OiCq MUTEUXNQ M{DVfGlEPTB;MUCg{txO M{WxblI{QDR2MEO4
U2OS MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUKxNEDPxE1? Mn\SO|IhcA>? M{DDbGROW09? MWXJR|UxRTFyIN88US=> M2rzOVI{QDR2MEO4
U251 MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYqxNEDPxE1? MVu3NkBp NXzzPW9mTE2VTx?= NVOzN2NtUUN3ME2xNEDPxE1? MmjqNlM5PDRyM{i=
UACC-812 NWHKbYdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmxNEDPxE1? NXS2SWFPPzJiaB?= M3jJfGROW09? MUnJR|UxRTFyIN88US=> NFjlV44zOzh2NECzPC=>
YAPC NYHuUIZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\oNVAh|ryP M4P4fFczKGh? MUDEUXNQ NHLJ[2tKSzVyPUGwJO69VQ>? MmrvNlM5PDRyM{i=
ZR-75-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIC5RmEyOCEQvF2= NX;M[FUyPzJiaB?= M{fSPGROW09? M2TXfGlEPTB;MUCg{txO MYeyN|g1PDB|OB?=
A375 MkXwSpVv[3Srb36gZZN{[Xl? MXqxMlIh|ryP NEPMeVU1KGh? MmW3SG1UVw>? MlLPTY5pcWKrdHnvckBw\iCyaH;zdIhwenmuYYTpc44hd2ZiTVXLMEBGWktuIHHu[EBUPlB? MnK2NlI{QDl2N{G=
YUSIT1 M{CySWZ2dmO2aX;uJIF{e2G7 NXj0UYZwTE2VTx?= NVqzWVk2emWmdXPl[EB{\W6|aYTpeol1gSC5aYToJGlEPTBiPjCwMlUh|ryP M1X4TFIzOzh7NEex
MeWo MmL0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnzPSG1UVw>? MlLGTWM2OCB;IEm4O{BvVQ>? NV3TNYxFOjZyMUi1NlQ>
WiDr M3PLfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVvEUXNQ NEX2XYhKSzVyIE2gO|Yhdk1? M1H0XlI3ODF6NUK0
Colo-205 MojlSpVv[3Srb36gZZN{[Xl? NFnhZY4yKM7:TR?= NFrHW3U1KGR? NFrJdpZFVVOR MnPuTY5lfWOnZDDhJIhq\2iueTDjc41x[XKjYnzlJINwdXCjY4Tpc44heGinbn;0fZBm MkPUNlU{QDFzNUK=
RBW-1 NHzqdoFHfW6ldHnvckBie3OjeR?= MoLhNUDPxE1? NFfrNIlFVVOR M4j4dW5wKHKnZIXjeIlwdiCxZjDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>? NGDXTm4zPDh6NU[5NC=>
RBO-1 MoDqSpVv[3Srb36gZZN{[Xl? NVjEeodkOSEQvF2= MUPEUXNQ MYDJcohq[mm2aX;uJI9nKE2nazCxM|IheGixc4Doc5J6dGG2aX;u MXeyOFg5PTZ7MB?=
RBO-2 M131eGZ2dmO2aX;uJIF{e2G7 MlL3NUDPxE1? M3nrc2ROW09? NVe4[GV[UW6qaXLpeIlwdiCxZjCgUYVsKDFxMjDwbI9{eGixconsZZRqd25? M3\DW|I1QDh3Nkmw
RBOW M4j5V2Z2dmO2aX;uJIF{e2G7 MmK2NUDPxE1? M2Xs[2ROW09? MlTRTY5pcWKrdHnvckBw\iBiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44> NFnye3gzPDh6NU[5NC=>
M257 NF\ZRolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXexNFAhdk1? M3XOTVczKGh? MkHiSI9meyCwb4SgbY5pcWKrdDDwdo9tcW[ncnH0bY9vKG:oIF2yOVch[2WubDDoZZJjd3W{aX7nJJdqdGRidInw[UBDWkGI M4\yclI{OzF5NES2
LCP NVTsXJJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnKwNVAxKG6P MYO3NkBp MVvJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhVEOSIHPlcIwhcGG{Yn;1dolv\yCEUlHGJHY3ODCUIH31eIFvfGG2aX;u NWTPVHVPOjN|MUe0OFY>
WM266 NX3VVHlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmxNFAhdk1? M3W3NVczKGh? NXz2VFZSUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFFFKG23dHHueIF1cW:w NX\P[YM1OjN|MUe0OFY>
M257 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfwV5cyODBibl2= M3HxdVczKGh? M1LWWWRw\XNibn;0JIlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDNNlU4KGOnbHygbIFz[m:3cnnu[{B4cWymIIT5dIUhSlKDRh?= MViyN|MyPzR2Nh?=
LCP MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:1NVAxKG6P NHSz[lE4OiCq Ml;hTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>? MUCyN|MyPzR2Nh?=
WM266 NGHOemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOxNFAhdk1? MoDnO|IhcA>? NEHLXXRKdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gW20zPjZiY3XscEBp[XKkb4XybY5oKEKUQV[gWlYxOERibYX0ZY51[XSrb36= MlTPNlM{OTd2NE[=

... Click to View More Cell Line Experimental Data

In vivo Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. [1]

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (57.74 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 519.56
Formula

C23H20F3N5O2S2

CAS No. 1195765-45-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03272464 Recruiting Melanoma Massachusetts General Hospital|Incyte Corporation November 30 2018 Phase 1
NCT03668431 Recruiting Metastatic Colorectal Cancer Massachusetts General Hospital|Novartis|Stand Up To Cancer October 15 2018 Phase 2
NCT02672358 Withdrawn Non-Small-Cell Lung Cancer Novartis Pharmaceuticals|Novartis September 3 2018 Phase 2
NCT03551626 Recruiting Malignant Melanoma Novartis Pharmaceuticals|Novartis August 29 2018 Phase 3
NCT03455764 Recruiting Melanoma Dana-Farber Cancer Institute|Novartis June 22 2018 Phase 1|Phase 2
NCT03553329 Completed Unresecable Stage IIIc or IV Melanoma Poitiers University Hospital June 2 2018 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products3

Tags: buy Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) supplier | purchase Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) cost | Dabrafenib (GSK2118436) manufacturer | order Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID